1  home treatment; 299 of the 461 treated with alprostadil (64.9 percent) had intercourse successfully

2   We investigated the efficacy and safety of alprostadil formulated for intracavernosal treatment in

3 gher response rates with increasing doses of alprostadil (from 2.5 to 20 microg).

4 le dysfunction, intracavernosal injection of alprostadil is an effective therapy with tolerable side

5  treatment with either the effective dose of alprostadil or placebo for three months at home.

6               We evaluated a system by which alprostadil (prostaglandin E1) is delivered transurethra

7                                              Alprostadil was delivered transurethrally in a double-bl

8 dose-response study of 296 men, all doses of alprostadil were superior to placebo and there was a sig